新诊断老年多发性骨髓瘤的预后分层及治疗进展

Prognostic stratification and treatment progress in elderly patients with newly diagnosed multiple myeloma

多发性骨髓瘤是一种好发于中老年人的浆细胞恶性增殖性疾病,目前仍不可治愈,中位诊断年龄为69岁,50%以上的患者在诊断时年龄大于75岁。近年来新药的应用显著改善了多发性骨髓瘤患者的总生存期和无进展生存期,但标准方案并不能让老年多发性骨髓瘤患者受益,可能还会降低患者生活质量,增加死亡率。因此,精准的预后评估及危险度分层对于实施个体化治疗至关重要。本文就老年多发性骨髓瘤治疗特点、预后分层及治疗进展做一综述。

Multiple myeloma(MM)is a malignant proliferative disease of plasma cells that occur in middle-aged and elderly people.It is still incurable.The median diagnostic age is 69 years old,and more than 50%of patients are older than 75 years old at the time of diagnosis.In recent years,the application of new drugs has significantly improved the overall survival and progression-free survival of patients with MM,but the standard regimen does not benefit elderly MM patients,and may also reduce the quality of life and increase mortality.Therefore,the accurate prognostic assessment and risk stratification are essential for individualized treatment.This article reviews the treatment characteristics,prognostic stratification and treatment progress of MM in the elderly.